LEXX (Lexaria Bioscience Corp.) Company Value to Revenue Ratio

Public company logo of Lexaria Bioscience Corp (LEXX)

Lexaria Bioscience is optimizing drug delivery, thereby reducing raw material costs. Scientific discoveries and licenses, which remain largely independent of economic cycles, serve as the primary drivers. Unique intellectual property allows the brand to maintain a profitable niche. The price-to-sales multiple trend confirms these theses, while the 26842.11 indicator reflects the status of the business's current market valuation.

LEXX Lexaria Bioscience Corp. Enterprise Value-to-Revenue Ratio (11/23/2025 - 11/19/2026)

Lexaria Bioscience - analytical breakdowns and key metrics (LEXX)

- business market valuation indicators:
Fundamental valuation:Lexaria Bioscience Corp LEXX
Original product of Lexaria

This indicator measures the real value of the business net of debt obligations relative to generated revenue, allowing investors to filter out market noise and assess the fundamental stability of assets. By analyzing the enterprise value-to-revenue ratio on GURU.Markets, an investor can see how patent wars with pharma behemoths over bioavailability methods impact the market capitalization of Lexaria Bioscience (LEXX), determining the fairness of the current valuation.

Competitor analysis for Lexaria Bioscience

HLN: Enterprise Value-to-Revenue Ratio|Kenvue Corp (KVUE) - Enterprise Value-to-Revenue Ratio|Verona Pharma PLC - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Jyong Biotech Ltd|EV/Sales Multiple Ligand Corp|EV/Sales Multiple AMRX|Total Company Value-to-Revenue Ratio Perrigo Company plc|EV/Sales Multiple ALVO (Alvotech Biopharmaceuticals)|LQDA: Company Value to Revenue Ratio|Galapagos N.V. - EV/Sales Multiple|ANIP - EV/Sales Multiple|MNKD: EV/Sales Multiple|amphastar.com (AMPH) - EV/Sales Multiple|PCRX (Pacira Pharmaceuticals) - EV/Sales Multiple|Company Value to Revenue ARS Pharmaceuticals, Inc. (SPRY)|EV/Sales Multiple TBPH|AQST (Aquestive Therapeutics) - Business Value to Revenue|scPharmaceuticals, Inc. - Company Value to Revenue|Business Value to Revenue TECX|tonixpharma.com - EV/Sales Multiple|Business Value to Revenue SXTC (sxtchina.com)|Eupraxia Pharma (EPRX) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue BioHarvest|Company Value to Revenue EXOZ|Company Value to Revenue Oramed Pharmaceuticals (ORMP)|Company Value to Revenue ENTX (Entera Bio Corp)|MindWalk Holdings Inc. - Company Value to Revenue Ratio|EV/Sales Multiple ABVC (ABVC BioPharma Inc)|CPIX - Company Value to Revenue|Quantum BioPharma Corp - EV/Sales Multiple|FGEN (fibrogen.com) - Company Value to Revenue Ratio|TELO (Telomir Pharmaceuticals) - Company Value to Revenue|Rani Therapeutics Holdings - Business Value to Revenue|Company Value to Revenue SNYR|Enterprise Value-to-Revenue Multiple rallybio.com RLYB|EV/Sales Multiple PULM|PTHL: Enterprise Value to Sales Volume|EV/Sales Multiple APM (Aptorum Group Ltd)|LYRA - Company Value to Revenue|Impact BioMedical Inc - EV/Sales Multiple|Enterprise Value to Sales Volume TNFA|YCBD (cbdmd.com) - Company Value to Revenue|painreform.com - Business Value to Revenue|Company Value to Revenue CYTO|Enterprise Value-to-Revenue Ratio LIPO|Enterprise Value-to-Revenue Ratio optinose.com (OPTN)|PIRS (Pieris Pharma) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Procaps Group S.A. PROC|Total Company Value-to-Revenue Ratio petrospharma.com (PTPI)|QLI - Enterprise Value-to-Revenue Ratio|Business Value to Revenue SLRN (ACELYRIN)|TFF Pharmaceuticals, Inc (TFFP) - Enterprise Value-to-Revenue Ratio